Abstract: Lung toxicity of chromium fumes (Cr fumes) was examined by a single intratracheal instillation into rats of 10.6 mg and 21.3 mg Cr fumes/kg body weight and by repeated (3 times) instillations of 10.8 mg and 21.7 mg Cr fumes/kg. The pathological changes were compared with those induced by single administrations of 3.2 mg and 19.2 mg Na2CO3 solution-insoluble fraction of Cr fumes (Cr-Fr)/kg and 20.8 mg commercially available chromium (III) oxide powder (Cr (III) oxide)/kg. Single and repeated administrations of Cr fumes suppressed growth rate in a dosedependent manner, but administrations of Cr-Fr and Cr (III) oxide did not. A single administration of Cr fumes produced granulomas in the entire airways and alveoli with progressive fibrotic changes, as well as severe mobilization and destruction of macrophages and foamy cells. Those histopathological changes were aggravated by the repeated administration of Cr fumes. On the other hand, single administrations of Cr-Fr and Cr (III) oxide produced no remarkable histopathological changes. Cr fumes were found to be composed of 73.5% chromium (III) oxide and 26.5% chromium (VI) oxide. The primary particles of Cr fumes and Cr-Fr were similar, 0.02 pm in size (6g:1.25), and Cr (III) oxide particles were 0.30 pm in size (6 g:1.53), measured by analytical electron microscopy (ATEM). Diffuse clusters of the primary particles in Cr fumes were identified as Cr (VI) oxide. The present results suggested that the lung toxicity of Cr fumes was mainly caused by these Cr (VI) oxide (Cr03) particles in Cr fumes.
Introduction
Various kinds of ferrous and non-ferrous chromium alloys have been widely used in industry', because of their excellent properties of heat resistance, antiabrasion and anticorrosion2~.
Much concern has been raised about adverse effects on the health of workers exposed to chromium and its compounds in various work environments, such as smelting and refining, welding, electroplating, tanning processes, pigment and *To whom correspondence should be addressed .
cement productions. An acute phase of human exposure to chromium fumes was characterized by metal fume fever, pneumonitis, coughs with production of large amounts of greenish mucoid sputum, audible wheezing in the chest, headache, substernal pain and dyspnea3~. The subacute and chronic phases of chromium poisoning were reported to result in perforation of the nasal septum, loss of olfactory sensation4~, skin ulceration, bronchial asthma5' 6) and lung cancer in addition to the abovementioned respiratory signs and symptoms. Jindrichova'~ reported that 11 welders using chromium-containing electrodes and excreting significantly
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a high urinary content of chromium exhibited a high prevalence of chronic coughs (100%), bronchitis (72%), atrophic rhinitis (54%), pharyngitis (45%), nasal septum erosion (35%) and chronic laryngitis (11 %) . Chromium and its compounds are now designated as a confirmed human carcinogen by IARC8~, ACGIH9~ and the Japan Society for Occupational Health10>.
There is a paucity of experimental toxicological data"-13) on acute and subacute effects of chromium and its compounds on the respiratory system, as compared with abundant information about the chronic and carcinogenic effects of these compounds. Adachi 14) and Adachi et al. 15 ) demonstrated that the long-term inhalation exposure of mice to chromic acid mists produced perforated nasal septum and adenocarcinomas.
Skin ulceration in guinea pigsl6~ and alveolar bronchiolization in mice'' were also reported as principal signs of chronic chromium poisoning. The lung toxicity of metallic fumes is considered to be affected by physical and chemical properties of the particles, because the particle size of aluminum oxide and titanium oxide was reported to influence the lung toxicity'8' 19), and because chromium (VI) oxide was much more toxic than chromium (III) oxide20~. The present study was intended to examine the lung toxicity of chromium fumes (Cr fumes) in rats administered intratracheally in single and repeated doses. In order to look into what kinds of oxidized components of Cr fumes contributed principally to the lung toxicity of Cr fumes, the insoluble fraction of Cr fumes in Na2CO3 solution (Cr-Fr) and a commercial reagent of chromium (III) powder (Cr (III) oxide) were administered intratracheally in a single dose. Gross and histopathological changes in the lung and growth rate of the rats instilled intratracheally with the three kinds of particulate materials were examined as toxicity indices.
The physical and chemical characteristics of the particulate materials were also examined for causative factors in the lung toxicity induced by Cr fumes.
Materials and Methods

Animals
Male rats of the Sprague-Dawley strain (Crj: CD) were purchased from Charles River Japan at the age of 4 weeks and housed in wire-meshed cages (5 rats/cage) in our animal facility. The animal room was maintained at a temperature of 24 ± 1°C, a relative humidity of 55 ± 5 % and an automatic lighting schedule of a 12-hr light (8:00-20:00)/ 12-hr dark (20:00-8:00) cycle. The rats were allowed free access to autoclaved food pellets (CE-2, CLEA Japan) and tap water sterilized by ultraviolet irradiation.
Preparation of the particulate materials Three kinds of particulate materials, Cr fumes, Cr-Fr and Cr (III) oxide, were examined in the present study. Cr fumes, generated by feeding metallic chromium powder (Reagent grade more than 99.9% pure, Soekawa Chemicals, Japan) into a plasma flame metal sprayer21~, were released into an aerosol chamber. The fumes in the chamber were collected on the surface of glass beads by means of a granular bed type fume collector. The collected Cr fumes were separated from the glass beads with a 250 mesh sieve. The Cr-Fr was obtained by the Na2CO3 leaching method22,23~: Cr fumes were put into in a 100 ml teflon tube, into which 7% Na2CO3 solution was added. The solution was ultrasonically dispersed for 15 min, then rigorously agitated in a water bath for lhr at 90°C. The insoluble residue was recovered by centrifugation with 10,000 rpm (11,000 x g) for 30 min. The recovered residue was neutralized with O.1 N HCl and then washed with distilled water 3 times and dried in a silica gel desiccator.
Cr (III) oxide was purchased from Nippon Chemical Industry (Japan).
Characterization of the particulate materials
Cr fumes were suspended in a 7% Na2CO3 solution for 1 hour at 90°C. After rigorous agitation and subsequent centrifugation of the suspension, the Cr (VI) in the supernatant was quantified by atomic absorption spectrometry (absorption peak at 359.3 nm measured with Hitachi 6000, Hitachi Co., Japan). A calibration curve for the quantification was prepared with commercially available standard Cr solutions. The analysis was repeated for 5 times and the mean value was used as Cr (VI). The residue of such treatment was weighed as Cr-Fr. The solution obtained by washing the residual Cr-Fr fraction 3 times with distilled water was submitted to the same atomic absorption analysis as described above.
The particle size, oxidation state and crystalline state of Cr fumes, Cr-Fr and Cr (III) oxide were determined by means of an analytical transmission electron microscope (ATEM; H-8000, Hitachi Co., Japan, equipped with an energy dispersive X-ray (EDX) microanalyzer, Kevex Delta IV, U.S.A) as follows: An appropriate amount of these particulate materials was dispersed in distilled water and sonicated for 30 sec. The suspensions of l ul each were placed on EM grids with carbon enforced collodion film. The particle sizes of these particulate materials were measured on the electron micrographs optically enlarged by an appropriate magnifications of the negative taken with the ATEM. The chemical composition and oxidation state of each particulate material was measured by EDX, and the crystalline state was examined by selected area electron diffraction (SAED) analysis.
Experimental design Table 1 shows the experimental design of intratracheal instillations of chromium particles. Cr fumes, Cr-Fr or Cr (III) oxide dispersed in 0.5 ml of saline was instilled intratracheally to rats. Each 8-week-old rat weighing 270-290 g was anesthetized with ether. Under direct observation of the larynx with a dissecting microscope, the rat received intratracheal intubation of the region near the carina. After insertion of the tracheal canula, a saline solution of Cr fumes, Cr-Fr or Cr (III) oxide was instilled into the lungs during the inspiration phase with 0.5 ml of expired gas, expecting possible uniform distribution of the dust into the lungs. The control group of rats received saline in the same manner. The dose levels of Cr fumes were determined by our preliminary study demonstrating that LD1~ of Cr fumes was approximately 74 mg/kg.
Histopathological preparations of the lung tissues
Five rats in each dose group were sacrificed in 1, 2, 4, 8 and 12 weeks after the intratracheal instillations. Each rat was anesthetized with pentobarbital sodium (60 mg/kg, i.p.) and then bled to death by cutting the abdominal aorta. Before open thoracostomy, either formaldehyde gas for a single, acute instillation of Cr fumes or 1.5 ml of 10% phosphatebuffered formalin solution for other treatment groups was introduced into the lungs, and then the trachea was ligated. After gross observation, the lungs and major visceral organs were fixed in the same fixative for 5-7 days. About 3 mm thick slices of the right lung were cut along the longitudinal axis of the main bronchus and other slices were cut vertically to the bronchial axis. Five to six frontal sections were also taken from the left lung, dehydrated and embedded in paraffin. The paraffin sections, 5 ,um thick, were stained with hematoxylin and eosin (HE) and Periodic Acid Schiff (PAS). Mallory's azan stain and silver impregnation were also used when needed.
Histopathological evaluation of the affected lungs
Histopathological changes in the lungs of the rats administered Cr fumes, Cr-Fr and Cr (III) oxide were examined for the following 9 items: 1) cloudy swelling and mucoid degeneration, 2) regeneration of the bronchobronchiolar epithelium, 3) reactive hyperplasia, 4) exudation and accumulation of inflammatory cells and mobilization and destruction of macrophages, 5) foreign-body granuloma, 6) increased number and swelling of fibroblasts, 7) thickening of the alveolar wall and ducts due to increased collagenous materials, 8) proteinosis and 9) alveolar edema. Each of these histopathological changes was scored on a scale of increasing severity from 0 to 4 as follows: 0 indicates no change or the same changes as those observed in the lungs Results Growth rate In growth rate there was no difference between the 10.8 mg/kg administered rats and the controls.
Gross findings in the lungs
The single intratracheal instillation of 10.6 and 21.3 mg Cr fumes/kg caused marked swelling of the lungs, brown induration of the pulmonary hilus and sporadic hemorrhagic patches. These lesions were recovered for the time being but crater-like induration on the surface of the lungs was observed during 8 weeks after the administration. On the other hand, the lungs of the rats administered 3.2 and 19.2 mg Cr-Fr/kg and 20.8 mg Cr (III) oxide/kg were characterized by a greenish hilus resulting presumably from deposition of Cr-Fr and Cr (III) oxide.
Repeated intratracheal instillation of Cr fumes produced essentially the same patterns of gross changes as those observed with the single instillation. The changes extended over the entire lobes and continued to be observed for 8
weeks after the last administration. Tables 2 and 3 summarize the histopathological changes in the rat lungs during the time course after single and repeated instillations of Cr fumes and histopathological changes after single instillations of Cr-Fr and Cr (III) oxide, respectively.
Histopathological change in the lungs
Bronchi and bronchioles: A single instillation of Cr fumes produced degeneration and swelling of the bronchial and bronchiolar epithelium and hyperplasia of the goblet cells as well as bronchial obstruction due to increased mucous secretion (Fig. 4A) . The granuloma tissue containing Cr fume particles, broncho-bronchiolitis and pen-bronchial inflammation as well as severe obstructive bronchiolitis were observed (Fig. 4B ). Fbbrotic changes in the less marked granuloma as well as the obstructive bronchiolitis still remained 8 weeks after a single injection of Cr fumes. The repeated instillations of Cr fumes produced the same types of histopathological changes as the single instillation. Severer bronchial degeneration and regeneration and granuloma leading to marked fibrotic change were observed after the repeated instillation. Cr-Fr produced neither granuloma nor bronchiolitis except for a very slight hyperplasia in the broncho-bronchiolar epithelium. Cr (III) oxide produced a very slight degeneration but that lesion ceased by 8 weeks. Bronchio-alveolar junction: The characteristics of the lesions found in the alveolar duct were the same as those observed in the airways, consisting predominantly of the granulomatous change. The granuloma was composed of alveolar macrophages, lymphocytes, fibroblasts and giant cells. The histopathological changes caused by the repeated instillations of Cr fumes were of the same degree of severity as those caused by the single instillation. Cr-Fr produced a slight focal hyperplasia of the epithelium, and a slight influx of mononuclear cells but neither granuloma nor obstructive bronchiolitis was observed (Fig. 4C) . A slight degeneration of the alveolar duct produced by Cr (III) oxide was recovered by 8 weeks after the instillation and neither inflammation nor fibrotic change was observed in the duct (Fig. 4D) .
Alveoli: The single instillations of 10.6 and 21.3 mg Cr fumes/kg produced ectatic emphysema and atelectasis characterized by mobilization and destruction of macrophages and of foamy cells in the alveoli. Thickening and fibrotic changes in the alveolar wall and fibrotic changes in the granuloma progressed for the entire timecourse after the single instillation. Peri-arteritis and inflammation of alveoli were observed in the early period of exposure but Physical and chemical properties of particulate materials It was found by atomic absorption spectrometry that 1.5% of Cr fumes was water-soluble and 12.3% of Cr fumes was soluble in the Na2CO3 solution. These species are both considered to be Cr (VI). It was also confirmed that the solution obtained by washing the residual Cr-Fr fraction 3 times with distilled water contain less than 1 % Cr (VI). A total of 13.8% Cr (VI) is equivalent to 26.5% Cr (VI) oxide (Cr03) in Cr fumes. The residue of 73.5% is, therefore, assumed to be Cr (III) oxide (Cr203) in Cr fumes. As a result, it was considered that Cr fumes were composed of 73.5% Cr (III) oxide and 26.5% Cr (VI) oxide which consisted of 11% water-soluble Cr (VI) oxide and 89% water-insoluble but Na2CO3 solution-soluble Cr (VI) oxide.
TEM photographs of these particulate materials are shown in Fig. 5 . Cr fumes were composed of fine crystalline particles (indicated as B in Fig. 5-1 ) and non-crystalline amorphous clusters (A). Cr-Fr was composed of very fine crystalline particles ( Fig. 5-2) . Cr (III) oxide consisted of relatively larger crystalline particles according to the SAED analysis ( Fig. 5-3) .
As shown in Figs. 5-1 and 5-2, the particle sizes of crystalline particles (B) in Cr fumes and those of Cr-Fr were basically similar, about 0.02-0.03 µm in diameter, but the particles of Cr (III) oxide were much larger, 0.30 ,um in diameter. Their 6g of Cr fumes, Cr-Fr and Cr (III) oxide was also similar with 1.3-1.5.
The EDX spectra of these particulate materials are shown in Fig. 5-AND . It was confirmed that the Cr fumes are composed of two kinds of particles of Cr oxides with different EDX spectra: The EDX spectra of particle B are similar to those of Cr-Fr (C) and Cr (III) oxide (D), but those of particle A had relatively higher peaks of oxygen than those of Cr-Fr and Cr (III) oxide. Judging from the ratio of oxygen to Cr peak, it was concluded that particle A was composed of Cr (VI) oxide and particles B, C and D were of Cr (III) oxide. The present findings obtained with chromium fumeinstilled rats are considered to correspond to an acute phase of human chromium poisoning resulting from inhalation exposure to chromic (VI) acid mist. Human chromium poisoning was characterized by coughing and the production of a large amount of greenish mucoid sputum, dyspnea and substernal pain as well as decreased body weight3>.
It can, therefore, be suggested in view of the results of the present study that severe pathological changes in the lungs as well as retarded growth rate of the rat intratracheally given chromium fume were caused by hexavalent chromium oxide particles in the fumes. 
